Human Growth Hormone (HGH) Market Analysis Report, Share, Trends, and Overview 2021-2030.

The Human Growth Hormone (HGH) Market is projected to grow from USD XX billion in 2021 to USD XX billion in 2028 at a CAGR of XX% in the 2021-2030 period. Human growth hormone (HGH), also known as somatotropin, is a peptide hormone accountable for growth stimulation, cell multiplication, and cell regeneration in humans and is the main component for human development. Growth hormone (GH) deficiency in humans is manifested when the pituitary gland does not synthesize enough concentration of HGH. This deficiency in humans is treated by injecting recombinant human growth hormone by subcutaneous administration. Various genetic disorders, including Prader-Willi syndrome and Turner syndrome, may also be the resultant cause for growth hormone deficiency in humans, leading to late puberty and stunted height.
According to data presented by the American Academy of Pediatrics, growth hormone deficiency among humans is a rare condition and impacts less than one in 3,000 to one in 10,000 children in U.S. At present, HGH is highly abused as an anti-aging treatment in older adults and as a performance-enhancing anabolic drug by weight-training enthusiasts and athletes. However, HGH is a regulated substance as per the USFDA and has not been approved for anti-aging and performance-enhancing indications.

COVID-19 Impact on Human Growth Hormone (HGH) Market

A research article published in Frontiers in Endocrinology Journal November 2020, patients with decreased growth hormone secretion comprise a risk complication for COVID-19 disease which requires focus on precautionary measures in susceptible individuals.

Furthermore, patients with Prader-Willi syndrome should take extra precautions to minimize the risk of getting COVID-19. Moreover, Prader-Willi syndrome patients may not display common symptoms such as a high temperature and they may also experience a higher-than-normal pain initiation which may defer the diagnosis of COVID-19.